Chen Yan, MD
Neurology · Cleveland, OHNPI 1487017489
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novartis at 34.0% of the total. Reporting peaked in 2022 at $192 and has fallen 91.5% since, to $16 in 2024. That places this record below the midpoint for neurology clinicians in OH, where the typical reported total is $970.
Across 19 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$125
- Sanofi$75
- Biogen$50
- Genentech USA, Inc.$45
- EMD Serono, Inc.$24
- UCB, Inc.$21
- plus $29 from 2 others
What the payments were for
- Food & beverage$368100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $125 |
| Sanofi | 4 | $75 |
| Biogen | 3 | $50 |
| Genentech USA, Inc. | 2 | $45 |
| EMD Serono, Inc. | 1 | $24 |
| UCB, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Bristol Myers Squibb | 1 | $12 |
How this compares
$368 in reported general payments places this provider in the 35th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 85 | $2,311 |
| Propranolol Hcl ErPropranolol Hcl | 29 | $1,250 |
| Baclofen | 49 | $951 |
| Memantine Hcl | 42 | $835 |
| Primidone | 26 | $673 |
| Donepezil Hcl | 41 | $578 |
| Oxcarbazepine | 11 | $506 |
| Topiramate | 34 | $481 |
| Pregabalin | 16 | $432 |
| Levetiracetam | 27 | $431 |
| Tizanidine Hcl | 26 | $395 |
| Methocarbamol | 11 | $348 |
| Escitalopram Oxalate | 13 | $147 |
| Quetiapine Fumarate | 14 | $127 |
| Sumatriptan Succinate | 17 | $41 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.